Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some efficacy and key safety-adjacent claims align with provided label excerpts (e.g., relapse rate reduction, MRI lesion reduction, dosing route/schedule, depression, injection-site reactions, hepatic injury, anaphylaxis described as rare). However, multiple mechanism-of-action statements, several quantitative adverse event prevalence claims, long-term extension/5-year durability assertions, disability progression and EDSS delay claims, and cross-product/marketing/patent/approval-history statements are unsupported or contradicted by the supplied label excerpts.
Category Scores
Accurate Statements
Betaseron is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
1 INDICATIONS AND USAGE
Betaseron reduces relapse rates in RRMS.
14 CLINICAL STUDIES (Study 1; annual exacerbation rate Table 3)
Clinical trials show Betaseron cuts annual exacerbation/relapse rates by about 30% versus placebo (e.g., annual exacerbation rate 1.31 placebo vs 0.90/0.9 on BETASERON 0.25 mg).
14 CLINICAL STUDIES (Study 1 Table 3; ~31% reduction)
Betaseron has MRI lesion reduction (e.g., change in MRI lesion area and frequent MRI scans with fewer new/expanding lesions).
14 CLINICAL STUDIES (Study 1 MRI endpoints; Figure 1; frequent MRI scans results)
Betaseron dosing is subcutaneous every other day.
2 DOSAGE AND ADMINISTRATION (2.1 Dosing Information)
Injection site reactions occur with Betaseron.
5.5 Injection Site Reactions Including Necrosis; 17 PATIENT COUNSELING
Liver enzyme elevations/transaminase elevations occur with Betaseron (hepatic injury section describes common asymptomatic transaminase elevations).
5.1 Hepatic Injury
Depression and suicide have been reported with Betaseron.
5.3 Depression and Suicide
Anaphylaxis has been reported as a rare complication of Betaseron.
5.2 Anaphylaxis and Other Allergic Reactions ("rare complication")
Neutralizing activity/neutralizing antibodies are reported in a subset of patients treated with Betaseron (e.g., 45% with serum neutralizing activity at one or more time points; ~30% in another measurement set).
6.2 Immunogenicity
Betaseron provides approximately 30% relapse reduction.
14 CLINICAL STUDIES (Study 1 Table 3; annual exacerbation rate 1.31 vs 0.90)
Betaseron includes immunomodulatory effects such as reduction of pro-inflammatory cytokine production.
12 CLINICAL PHARMACOLOGY 12.2 ("reduction of pro-inflammatory cytokine production")
Betaseron has some activity in active secondary progressive disease / SPMS with relapses.
1 INDICATIONS AND USAGE (active secondary progressive disease); 14 CLINICAL STUDIES (Studies 2 and 3 relapse incidence decreases)
Unsupported Statements
The benefits of Betaseron are sustained over 2-5 years.
Provided label excerpts include Study 1 (2 years) and Study 4 follow-up up to 2 years, but do not provide 5-year extension evidence in the supplied sections.
Betaseron inhibits T-cell activation.
No explicit statement of T-cell activation inhibition is present in the provided mechanism/pharmacodynamics text.
Betaseron limits blood-brain barrier leakage.
No blood-brain barrier/leakage claim appears in the supplied label excerpts.
Betaseron curbs autoimmune attacks on myelin in multiple sclerosis.
The provided sections use broader immunomodulatory language; the specific phrasing about autoimmune attacks on myelin is not present.
In the 1993 phase 3 trial, EDSS score increase was delayed by 9 months.
No "9 months" EDSS delay statement is present in the supplied sections.
A 5-year extension of the trial confirmed long-term efficacy of Betaseron.
No 5-year extension description is present in the supplied sections.
In the 5-year extension, 78% of treated patients were relapse-free vs 48% on placebo.
No such 5-year relapse-free percentages are present in the supplied sections.
Bayer Healthcare markets Betaseron.
No marketing/company information is included in the supplied label excerpts.
The FDA approved Betaseron in 1993 as the first multiple sclerosis disease-modifying therapy (DMT).
No approval-year or 'first DMT' language appears in the supplied label excerpts.
Flu-like symptoms (fever, chills, myalgia) affect 60-80% of patients initially with Betaseron.
The provided label excerpts do not include the specific numeric prevalence (60–80%) or the specified breakdown (fever/chills/myalgia) in that form.
Anaphylaxis is rare with Betaseron (<1%).
The label excerpt states anaphylaxis is rare but does not provide a <1% numeric rate in the supplied sections.
Neutralizing antibodies potentially reduce Betaseron efficacy.
The provided immunogenicity section states the relationship between antibody formation and clinical safety or efficacy is not known.
Betaseron is first-line for early RRMS.
No treatment-ranking or 'first-line' language is present in the supplied indications/usage excerpt.
Betaseron is less favored now due to the convenience of oral medications.
No comparative market preference statement appears in the supplied label excerpts.
Original Betaseron patents expired in the early 2000s.
No patent/Orange Book history is present in the supplied label excerpts.
Generics like Extavia (same molecule) launched in 2009.
No generic/launch-date information is present in the supplied label excerpts.
No active Orange Book patents block competition today for Betaseron.
No Orange Book/patent status information is present in the supplied label excerpts.
There is limited evidence for Betaseron in primary progressive multiple sclerosis (PPMS).
No PPMS evidence statement is present in the supplied label excerpts; the provided indications include relapsing forms.
Ocrevus is stated to outperform newer drugs compared to Betaseron in SPMS.
No cross-product comparative efficacy statement is present in the supplied label excerpts.
Contradictions
Low
AI Statement
Ocrevus is stated to outperform newer drugs compared to Betaseron in SPMS.
Label Reference
Provided label excerpts do not contain any Ocrevus comparison; cross-product superiority statements are absent from the provided label sections.
Important Omissions
Core safety-label elements beyond what was evaluated here (e.g., complete contraindication details already provided but not reflected in the AI’s extracted claims; boxed warning status; pregnancy/lactation and pediatric sections; additional monitoring requirements).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several extracted claims introduce unsupported efficacy durability, mechanism statements, and quantitative adverse-event prevalence figures. While some key safety topics (anaphylaxis described as rare, depression/suicide, hepatic injury, injection site reactions) align, unsupported/incorrect numeric or mechanistic claims could mislead interpretation of benefit/risk and monitoring expectations.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Multiple extracted claims are unsupported by the provided label excerpts (especially mechanistic statements and long-term extension/5-year efficacy figures, plus quantitative prevalence figures for flu-like symptoms and anaphylaxis rate).
Suggested Improvement
Restrict claims to statements explicitly supported by the provided label sections and avoid adding mechanistic specifics or numeric adverse-event prevalence not present in the excerpts. Remove unsupported 5-year extension/relapse-free percentages and the EDSS '9 months' delay statement unless supported by provided label text. Avoid cross-product comparisons and non-label marketing/patent/approval-history statements.